Consolidated Condensed Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 1,058,811	$ 1,126,124
Short-term investments	360,210	452,301
Accounts receivable	334,436	378,865
Other current assets	80,028	45,381
Total current assets	1,833,485	2,002,671
Equipment, net	12,434	15,514
Other long-term assets	18,667	18,667
Total assets	1,864,586	2,036,852
Current liabilities:
Accounts payable	266,058	263,573
Accrued expenses	774,752	782,579
Accrued warrant liability	44,412	6,414
Total current liabilities	1,085,222	1,052,566
Non-current liabilities
Total liabilities	1,085,222	1,052,566
Stockholders’ equity:
Preferred stock, $.005 par value; 1,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 0 shares issued and outstanding as of March 31, 2020 and December 31, 2019
Common stock, $.005 par value; 25,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 11,403,239 and 11,298,239 shares issued and outstanding as of March 31, 2020 and December 31, 2019	56,540	56,487
Additional paid-in capital	163,666,376	163,161,523
Accumulated other comprehensive loss	(642,507)	(568,030)
Accumulated deficit	(167,294,104)	(166,705,572)
Total Cleveland BioLabs, Inc. stockholders’ deficit	(4,213,695)	(4,055,592)
Noncontrolling interest in stockholders’ equity	4,993,059	5,039,878
Total stockholders’ equity	779,364	984,286
Total liabilities and stockholders’ equity	$ 1,864,586	$ 2,036,852